ReviewJournal of Cancer2014
Far beyond the usual biomarkers in breast cancer: a review.
Review in Journal of Cancer, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed.
- Exosomal transfer of miR-548aq-3p confers cisplatin resistanceAmerican journal of cancer research · 2023Article
- Quantitative digital histopathology and machine learning to predict pathological complete response to chemotherapy in breast cancer patients using pre-treatment tumor biopsies.Scientific reports · 2022Article
- Differences of time-dependent microRNA expressions in breast cancer cells.Non-coding RNA research · 2021Article
- Coexpression of Smac/DIABLO and Estrogen Receptor in breast cancer.Cancer biomarkers : section A of Disease markers · 2021Article
- Challenges and Opportunities in Clinical Applications of Blood-Based Proteomics in Cancer.Cancers · 2020Review
- Electrochemical Nanobiosensors for Detection of Breast Cancer Biomarkers.Sensors (Basel, Switzerland) · 2020Review
- The emerging role of mediator complex subunit 12 in tumorigenesis and response to chemotherapeutics.Cancer · 2020Review
- Impact of Molybdenum Compounds as Anticancer Agents.Bioinorganic chemistry and applications · 2019Review
- Detection and analysis of circulating large intergenic non-coding RNA regulator of reprogramming in plasma for breast cancer.Thoracic cancer · 2018Article
- Identification of potential serum biomarkers for breast cancer using a functional proteomics technology.Biomarker research · 2017Article
- Epigenetic regulation of glycosylation and the impact on chemo-resistance in breast and ovarian cancer.Epigenetics · 2016Review
- Long-range regulators of the lncRNA HOTAIR enhance its prognostic potential in breast cancer.Human molecular genetics · 2016Article
- Identification of functional metabolic biomarkers from lung cancer patient serum using PEP technology.Biomarker research · 2016Article
- Article
- The Role of MicroRNAs as Predictors of Response to Tamoxifen Treatment in Breast Cancer Patients.International journal of molecular sciences · 2015Review
- The prognostic value of intermedin in patients with breast cancer.Disease markers · 2015Article
- Expression of CDK8 and CDK8-interacting Genes as Potential Biomarkers in Breast Cancer.Current cancer drug targets · 2015Review
- High mobility group box-1 and its clinical value in breast cancer.OncoTargets and therapy · 2015Article
- Cancer: we should not forget the past.Journal of Cancer · 2015Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Research investigating biomarkers for early detection, prognosis and the prediction of treatment responses in breast cancer is rapidly expanding. However, no validated biomarker currently exists for use in routine clinical practice, and breast cancer detection and management remains dependent on invasive procedures. Histological examination remains the standard for diagnosis, whereas immunohistochemical and genetic tests are utilized for treatment decisions and prognosis determinations. Therefore, we conducted a comprehensive review of literature published in PubMed on breast cancer biomarkers between 2009 and 2013. The keywords that were used together were breast cancer, biomarkers, diagnosis, prognosis and drug response. The cited references of the manuscripts included in this review were also screened. We have comprehensively summarized the performance of several biomarkers for diagnosis, prognosis and predicted drug responses of breast cancer. Finally, we have identified 15 biomarkers that have demonstrated promise in initial studies and several miRNAs. At this point, such biomarkers must be rigorously validated in the clinical setting to be translated into clinically useful tests for the diagnosis, prognosis and prediction of drug responses of breast cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.